
## Feng Zhu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7741901/publications.pdf Version: 2024-02-01



FENC 741

#	Article	IF	CITATIONS
1	The role of T-LAK cell-originated protein kinase in targeted cancer therapy. Molecular and Cellular Biochemistry, 2022, 477, 759-769.	1.4	5
2	BCKDK Promotes Ovarian Cancer Proliferation and Migration by Activating the MEK/ERK Signaling Pathway. Journal of Oncology, 2022, 2022, 1-14.	0.6	5
3	TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC. Cell Death and Disease, 2022, 13, 450.	2.7	13
4	Targeting LIMK1 with luteolin inhibits the growth of lung cancer <i>in vitro</i> and <i>in vivo</i> . Journal of Cellular and Molecular Medicine, 2021, 25, 5560-5571.	1.6	32
5	Dasatinib Inhibits Lung Cancer Cell Growth and Patient Derived Tumor Growth in Mice by Targeting LIMK1. Frontiers in Cell and Developmental Biology, 2020, 8, 556532.	1.8	21
6	Ribosomal S6 protein kinase 4 promotes radioresistance in esophageal squamous cell carcinoma. Journal of Clinical Investigation, 2020, 130, 4301-4319.	3.9	30
7	Research Advances in the Molecular Functions and Relevant Diseases of TAOKs, Novel STE20 Kinase Family Members. Current Pharmaceutical Design, 2020, 26, 3122-3133.	0.9	2